Results 1 to 10 of about 42,055 (137)

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

Journal of Pharmacological Sciences, 2015
Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters
Kentaro Minami, Yoshinari Shinsato, Masatatsu Yamamoto, Homare Takahashi, Shaoxuan Zhang, Yukihiko Nishizawa, Sho Tabata, Ryuji Ikeda, Kohich Kawahara, Kazutake Tsujikawa, Kazuo Chijiiwa, Katsushi Yamada, Shin-ichi Akiyama, Sandra Pérez-Torras, Marcal Pastor-Anglada, Tatsuhiko Furukawa, Takeda Yasuo   +16 more
doaj   +5 more sources

GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer [PDF]

PeerJ, 2022
Background Pancreatic ductal adenocarcinoma (PDAC) has the worst five-year overall survival rate among all cancer types. Acquired chemoresistance is considered one of the main reasons for this dismal prognosis, and the mechanism of chemoresistance is ...
Chen Chen, Binfeng Wu, Mingge Wang, Jinghua Chen, Zhaohui Huang, Jin-Song Shi   +5 more
doaj   +4 more sources

Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer [PDF]

FASEB BioAdvances
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer‐related mortality, characterized by intrinsic resistance to conventional therapies and limited effective treatment options. In this study, we investigated the role of the CXCR2
Caitlin Molczyk, Reegan Sturgeon, Sugandha Saxena, Esther Johnson, Rakesh Bhatia, Namita Bhyravbhatla, Sushil Kumar, Surinder K. Batra, Rakesh K. Singh   +8 more
doaj   +2 more sources

Targeting ketone body metabolism in mitigating gemcitabine resistance. [PDF]

JCI Insight
Chemotherapy is often combined with surgery for muscle invasive and nonmuscle invasive bladder cancer (BCa). However, 70% of the patients recur within 5 years. Metabolic reprogramming is an emerging hallmark in cancer chemoresistance. Here, we report a gemcitabine resistance mechanism that promotes cancer reprogramming via the metabolic enzyme OXCT1 ...
Rohena-Rivera K, You S, Kim M, Billet S, Ten Hoeve J, Gonzales G, Huang C, Heard A, Chan KS, Bhowmick NA.   +9 more
europepmc   +3 more sources

Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer [PDF]

Biomolecules
Oral microbiota have been implicated in pancreatic ductal adenocarcinoma (PDAC) and may contribute to chemotherapy resistance. While previous studies attributed bacteria-induced resistance to indirect host modulation, recent findings suggest a direct ...
Geng Xu, Yaling Jiang, Chen Sun, Bernd W. Brandt, Kamran Nazmi, Luca Morelli, Giulia Lencioni, Elisa Giovannetti, Dongmei Deng   +8 more
doaj   +2 more sources

Integrated transcriptomic analysis identifies lactylation-linked gemcitabine resistance and therapeutic targets in intrahepatic cholangiocarcinoma [PDF]

Frontiers in Cell and Developmental Biology
BackgroundIntrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy of the bile ducts, and resistance to gemcitabine, a first-line chemotherapy, significantly complicates treatment.
Wenwei Xie, Wenwei Xie, Jialiang Hu, Jialiang Hu, Hanmei Xu, Hanmei Xu   +5 more
doaj   +2 more sources

The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability [PDF]

Cell Death and Disease
Gemcitabine resistance is a major clinical challenge in pancreatic cancer (PC); therefore, strategies to combat gemcitabine resistance are urgently required. Reprogramming pyrimidine metabolism by oncogenic signaling contributes to cancer progression and
Wenming Zhang, Rui Liu, Junwen Hu, Shuangyan Wan, Yeqin Zou, Tong Che, Jin Zhang, Leifeng Chen, Xiaogang Peng   +8 more
doaj   +2 more sources

CSN6 Promotes Pancreatic Cancer Progression and Gemcitabine Resistance via Antagonizing DCAF1‐Mediated Ubiquitination of NPM1 [PDF]

Advanced Science
Pancreatic ductal adenocarcinoma (PDAC) is a fatal cancer with poor prognosis. COP9 signalosome subunit 6 (CSN6), a key regulator of different E3 ubiquitin ligases, plays oncogenic roles in various cancers.
Yijing Zhang, Han Gao, Aiwen Tang, Haiwen Lyu, Zongmin Fan, Jiahui Guo, Yuzhi Wang, Hairong Yi, Qihao Pan, Haidan Luo, Baifu Qin, Boyu Zhang, Xiangqi Meng, Qingxin Liu, Mong‐Hong Lee   +14 more
doaj   +2 more sources

Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma [PDF]

Advanced Science
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with a dismal prognosis. Gemcitabine‐based chemotherapy has emerged as a first‐line treatment for PDAC.
Ying‐Qin Zhu, Yue Huang, Yin‐Hao Shi, Chen‐Song Huang, Guang‐Yin Zhao, Zhi‐De Liu, Ming‐Jian Ma, Jing‐Yuan Ye, Xiang Xu, Qi Liu, Xi‐Tai Huang, Jie‐Qin Wang, Qiong‐Cong Xu, Xiao‐Yu Yin   +13 more
doaj   +2 more sources

TRIM59/RBPJ positive feedback circuit confers gemcitabine resistance in pancreatic cancer by activating the Notch signaling pathway [PDF]

Cell Death and Disease
Pancreatic cancer (PC) is one of the most lethal malignant tumors that lacks effective treatment, and gemcitabine-based chemoresistance occurs frequently. Therefore, new therapeutic strategies for PC are urgently needed.
Shiyu Chen, Zhiwei He, Kun Cai, Yan Zhang, Hongyan Zhu, Chong Pang, Jiaqi Zhang, Dong Wang, Xundi Xu   +8 more
doaj   +2 more sources